ATE328074T1 - Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten - Google Patents

Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten

Info

Publication number
ATE328074T1
ATE328074T1 AT00910916T AT00910916T ATE328074T1 AT E328074 T1 ATE328074 T1 AT E328074T1 AT 00910916 T AT00910916 T AT 00910916T AT 00910916 T AT00910916 T AT 00910916T AT E328074 T1 ATE328074 T1 AT E328074T1
Authority
AT
Austria
Prior art keywords
secondary structure
antisense sequence
oligonucleotide
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT00910916T
Other languages
English (en)
Inventor
Claude Malvy
Andrei Maksimenko
Valerie Helin
Marina Gottikh
Original Assignee
Bioalliance Pharma Sa
Centre Nat Rech Scient
Inst Gustave Roussy Igr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma Sa, Centre Nat Rech Scient, Inst Gustave Roussy Igr filed Critical Bioalliance Pharma Sa
Application granted granted Critical
Publication of ATE328074T1 publication Critical patent/ATE328074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00910916T 1999-03-09 2000-03-09 Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten ATE328074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902921A FR2790757B1 (fr) 1999-03-09 1999-03-09 Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
ATE328074T1 true ATE328074T1 (de) 2006-06-15

Family

ID=9542992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910916T ATE328074T1 (de) 1999-03-09 2000-03-09 Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten

Country Status (12)

Country Link
US (1) US7022832B2 (de)
EP (1) EP1175489B1 (de)
JP (1) JP2004500018A (de)
AT (1) ATE328074T1 (de)
AU (1) AU3295700A (de)
CA (1) CA2363255A1 (de)
DE (1) DE60028367T2 (de)
DK (1) DK1175489T3 (de)
ES (1) ES2265916T3 (de)
FR (1) FR2790757B1 (de)
PT (1) PT1175489E (de)
WO (1) WO2000053745A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
US20090005332A1 (en) * 2004-12-30 2009-01-01 Hauser Todd M Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
EP1934348B1 (de) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon
WO2008039937A2 (en) * 2006-09-27 2008-04-03 Novarx Blocking of gene expression in eukaryotic cells
US7645578B2 (en) * 2006-10-31 2010-01-12 Agilent Technologies, Inc. Cleavage of RNA at redundant sites
ATE508191T1 (de) 2006-11-01 2011-05-15 Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
JP2012505657A (ja) 2008-10-15 2012-03-08 ソマジェニックス インク． 遺伝子発現の阻害のためのショートヘアピンｒｎａ
CN102264898B (zh) * 2008-10-23 2013-10-16 国立大学法人东京大学 微小rna的功能抑制方法
EP2454371B1 (de) 2009-07-13 2021-01-20 Somagenics, Inc. Chemische modifikation kleiner haarnadel-rnas zur genexpressionshemmung
EP2933333B1 (de) 2010-07-08 2018-02-21 Bonac Corporation Einsträngiges nukleinsäuremolekül zur genexpressionssteuerung
EP2639307B1 (de) 2010-08-03 2015-03-04 Bonac Corporation Einsträngiges Nukleinsäuremolekül mit stickstoffhaltigem alizyklischem Gerüst
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US20160040163A1 (en) * 2013-03-15 2016-02-11 Pronai Therapeutics, Inc. Dnai for the modulation of genes
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
CN106068324B (zh) 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
KR20170098914A (ko) 2014-12-27 2017-08-30 가부시키가이샤 보낙 유전자 발현 제어를 위한 천연형 miRNA 및 그의 용도
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN116262919A (zh) 2021-12-14 2023-06-16 成都凌泰氪生物技术有限公司 一种基于miRNA-2911的核酸分子
WO2025096807A2 (en) * 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL172710B1 (pl) * 1992-07-02 1997-11-28 Hybridon Inc Samostabilizujacy sie oligonukleotyd PL PL
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement

Also Published As

Publication number Publication date
US7022832B2 (en) 2006-04-04
FR2790757A1 (fr) 2000-09-15
WO2000053745A9 (fr) 2001-11-08
ES2265916T3 (es) 2007-03-01
EP1175489A1 (de) 2002-01-30
DK1175489T3 (da) 2006-10-02
CA2363255A1 (fr) 2000-09-14
DE60028367T2 (de) 2007-02-08
AU3295700A (en) 2000-09-28
EP1175489B1 (de) 2006-05-31
DE60028367D1 (de) 2006-07-06
JP2004500018A (ja) 2004-01-08
WO2000053745A1 (fr) 2000-09-14
FR2790757B1 (fr) 2003-08-01
US20020156261A1 (en) 2002-10-24
PT1175489E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
EP1798285B1 (de) Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
DE60325016D1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
WO2007143316A3 (en) Compounds and methods for modulating expression of sglt2
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1362600A4 (de) Pharmazeutische zusammensetzungen mit einem decoy und verfahren zu ihrer verwendung
DE69017983D1 (de) Anti-sens Nukleotidsequenz, anti-RNS des alpha-TNFS, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel und pharmazeutische Präparate davon.
WO2003101394A3 (en) Defensins: use as antiviral agents
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
EP1248635A4 (de) Antisense-modulation der glykogen-synthase-kinase-3alpha-expression
EP2327784A3 (de) Nukleinsäuren zur Hemmung der Expression de Hairless Proteins und Verfahren deren Benutzung
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
DE60117572T2 (de) Inhibitoren der Reversen Transkriptase von HIV aus tRNA
WO1997004087A1 (de) Ribozyme zur selektiven hemmung der expression von genen von mhc-allelen und diese enthaltende arzneimittel
DE50303606D1 (de) Decoy-oligonukleotid-hemmung der cd40-expression
WO2004035759A3 (en) Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175489

Country of ref document: EP

REN Ceased due to non-payment of the annual fee